Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways

Published:2022-05 Issue: Volume:296 Page:120427
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Jaidee Rattanaporn,Kukongviriyapan Veerapol,Senggunprai Laddawan,Prawan Auemduan,Jusakul Apinya,Laphanuwat Phatthamon,Kongpetch Sarinya

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference35 articles.

1. Molecular pathogenesis of intrahepatic cholangiocarcinoma;Andersen;J. Hepatobiliary Pancreat. Sci.,2014

2. Liver fluke induces cholangiocarcinoma;Sripa;PLoS Med.,2007

3. Pathogenesis, diagnosis, and management of cholangiocarcinoma;Rizvi;Gastroenterology,2013

4. Cancer control in Thailand;Vatanasapt;Jpn. J. Clin. Oncol.,2002

5. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 study;Valle;Br. J. Cancer,2009

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma;Cancer Letters;2024-07

2. Dual blockage of PI3K-mTOR and FGFR induced autophagic cell death in cholangiocarcinoma cells;Heliyon;2024-05

3. Expansion of the complex genotypic and phenotypic spectrum of FGFR2-associated neurocutaneous syndromes;Human Genetics;2024-01-24

4. Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies;Frontiers in Oncology;2024-01-24

5. Current Status and Progress of Systemic and Local Therapy for Intrahepatic Cholangiocarcinoma;Advances in Clinical Medicine;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3